The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Depression is a well-known serious mental illness, and the onset of treatment using
traditional antidepressants is frequently delayed by several weeks. Moreover, numerous …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Cognitive impairment has been observed in patients with various psychiatric disorders,
including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD) …

Neurological disorders are the leading cause of disability and the second leading cause of
death worldwide. The increasing social and economic burdens of neurological disorders are …

Abstract (R, S)-ketamine has prophylactic antidepressant-like effects in rodents; however,
the precise molecular mechanisms underlying its action remain unknown. Using RNA …

Multiple sclerosis (MS) is the most common demyelinating disease that attacks the central
nervous system. We recently reported that the new antidepressant (R)-ketamine could …

Over the past two decades, ketamine has emerged as a novel effective and rapid-acting
antidepressant. While the vast majority of studies on ketamine have focused on its ability to …

Abstract (S)-ketamine has been approved as a rapid-acting antidepressant drug (RAAD).
Although ketamine has an advantage over classic antidepressants (ADs) due to its rapid …